Smokovski Ivica, Steinle Nanette, Behnke Andrew, Bhaskar Sonu M M, Grech Godfrey, Richter Kneginja, Niklewski Günter, Birkenbihl Colin, Parini Paolo, Andrews Russell J, Bauchner Howard, Golubnitschaja Olga
University Clinic of Endocrinology, Diabetes and Metabolic Disorders, Skopje, North Macedonia.
Faculty of Medical Sciences, University Goce Delcev, Stip, North Macedonia.
EPMA J. 2024 May 11;15(2):149-162. doi: 10.1007/s13167-024-00364-6. eCollection 2024 Jun.
Non-communicable chronic diseases (NCDs) have become a major global health concern. They constitute the leading cause of disabilities, increased morbidity, mortality, and socio-economic disasters worldwide. Medical condition-specific digital biomarker (DB) panels have emerged as valuable tools to manage NCDs. DBs refer to the measurable and quantifiable physiological, behavioral, and environmental parameters collected for an individual through innovative digital health technologies, including wearables, smart devices, and medical sensors. By leveraging digital technologies, healthcare providers can gather real-time data and insights, enabling them to deliver more proactive and tailored interventions to individuals at risk and patients diagnosed with NCDs. Continuous monitoring of relevant health parameters through wearable devices or smartphone applications allows patients and clinicians to track the progression of NCDs in real time. With the introduction of digital biomarker monitoring (DBM), a new quality of primary and secondary healthcare is being offered with promising opportunities for health risk assessment and protection against health-to-disease transitions in vulnerable sub-populations. DBM enables healthcare providers to take the most cost-effective targeted preventive measures, to detect disease developments early, and to introduce personalized interventions. Consequently, they benefit the quality of life (QoL) of affected individuals, healthcare economy, and society at large. DBM is instrumental for the paradigm shift from reactive medical services to 3PM approach promoted by the European Association for Predictive, Preventive, and Personalized Medicine (EPMA) involving 3PM experts from 55 countries worldwide. This position manuscript consolidates multi-professional expertise in the area, demonstrating clinically relevant examples and providing the roadmap for implementing 3PM concepts facilitated through DBs.
非传染性慢性病(NCDs)已成为全球主要的健康问题。它们是全球范围内残疾、发病率上升、死亡率上升以及社会经济灾难的主要原因。针对特定医学状况的数字生物标志物(DB)面板已成为管理非传染性慢性病的宝贵工具。数字生物标志物是指通过创新的数字健康技术为个体收集的可测量和量化的生理、行为和环境参数,这些技术包括可穿戴设备、智能设备和医疗传感器。通过利用数字技术,医疗保健提供者可以收集实时数据和见解,从而能够为有风险的个体以及被诊断患有非传染性慢性病的患者提供更积极主动和量身定制的干预措施。通过可穿戴设备或智能手机应用程序持续监测相关健康参数,使患者和临床医生能够实时跟踪非传染性慢性病的进展。随着数字生物标志物监测(DBM)的引入,正在提供一种新的初级和二级医疗保健质量,为健康风险评估以及保护弱势群体预防健康向疾病转变带来了充满希望的机会。数字生物标志物监测使医疗保健提供者能够采取最具成本效益的有针对性的预防措施,尽早发现疾病发展情况,并引入个性化干预措施。因此,它们有益于受影响个体的生活质量(QoL)、医疗保健经济以及整个社会。数字生物标志物监测有助于实现从被动医疗服务向由欧洲预测、预防和个性化医学协会(EPMA)推动的3PM方法的范式转变,该协会有来自全球55个国家的3PM专家参与。本立场文件整合了该领域的多专业专业知识,展示了临床相关实例,并提供了通过数字生物标志物促进实施3PM概念的路线图。